Effect of Cdk5 antagonist on L-dopa-induced dyskinesias in a rat model of Parkinson's disease

International Journal of Neuroscience

Volumn 120, Issue 6, 2010, Pages 421-427

  Guan, Qiang ^a   Liu, Xueyuan ^a   He, Yusheng ^a   Jin, Lingjing ^a   Zhao, Lijuan ^a  

^a TONGJI UNIVERSITY   (China)

Author keywords

Cyclin dependent kinase 5 antagonist; Dopamine and cAMP regulated phosphoprotein of 32 kDa; Dyskinesias; L dopa; Parkinson's disease

Indexed keywords

APOMORPHINE; CYCLIN DEPENDENT KINASE 5; CYCLIN DEPENDENT KINASE INHIBITOR; LEVODOPA; PHOSPHOPROTEIN DARPP 32; ROSCOVITINE; THREONINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DYSKINESIA; FEMALE; GENE EXPRESSION REGULATION; MALE; NONHUMAN; PARKINSON DISEASE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; RAT; SINGLE DRUG DOSE; TREATMENT RESPONSE; UPREGULATION; WESTERN BLOTTING;

ANIMALS; ANTIPARASITIC AGENTS; CORPUS STRIATUM; CYCLIN-DEPENDENT KINASE 5; DISEASE MODELS, ANIMAL; DOPAMINE AND CAMP-REGULATED PHOSPHOPROTEIN 32; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MALE; OXIDOPAMINE; PARKINSONIAN DISORDERS; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PURINES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 77952847092     PISSN: 00207454     EISSN: 15635279     Source Type: Journal    
DOI: 10.3109/00207451003797694     Document Type: Article

References (27)

1. Aubert, I., Guigoni, C., Hakansson, K., Li, Q., Dovero, S., Barthe, N., et al. (2005). Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. Annals of Neurology, 57, 17-26.
2. Bibb, J. A., Che, J., Taylor, J. R., Svenningsson, P., Nishi, A., Snyder, G. L., et al. (2001). Effects of chronic exposure to cocaine are regulated by the neuronal protein Cdk5. Nature, 410, 376-380.
3. Bibb, J. A., Snyder, G. L., Nishi, A., Yan, Z.,Meijer, L., Fienberg, A. A., et al. (1999). Phosphorylation of DARPP-32 by Cdk5 modulates dopamine signalling in neurons. Nature, 402, 669-671.
4. Chergui, K., Svenningsson, P., & Greengard, P. (2004). Cyclindependent. kinase 5 regulates dopaminergic and glutamatergic transmission in the striatum. Proceedings of the National Academy of Science, 101(7), 2191-2196.
5. Chen, P. C., & Chen, J. C. (2005). Enhanced Cdk5 activity and p35 translocation in the ventral striatum of acute and chronic methamphetamine- treated rats. Neuropsychopharmacology, 30, 538-549.
6. Colosimo, C., Fabbrini, G., & Berardelli, A. (2006). Drug Insight: New drugs in development for Parkinson's disease. Nature Clinical Practice Neurology, 2(11), 600-610.
7. Damier, P. (2009).Drug-induced dyskinesias. Current Opinion in Neurology, 22(4), 394-399.
8. Dekundy, A., Lundblad, M., Danysz, W., & Cenci, M. A. (2007). Modulation of L-DOPA-induced abnormal involuntary movements by clinically tested compounds: Further validation of the rat dyskinesia model. Behavioural Brain Research, 179(1), 76-89.
9. Greengard, P., Allen, P. B., & Nairn, A. C. (1999). Beyond the dopamine receptor: The DARPP-32/protein phosphatase-1 cascade. Neuron, 23, 435-447.
10. Gerfen, C. R., Engber, T.M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., Jr., et al. (1990). D1 and D2 dopamine receptorregulated gene expression of striatonigral and striatopallidal neurons. Science, 250, 1429-1432.
11. Guan, Q., Zhan, Q., He, Y., & Tan, L. (2007). Changes in the prodynorphin gene and DARPP-32 state in 6-OHDA-lesioned rats following long-term treatment with l-dopa. Neuroscience Letters, 426(1), 64-68.
12. Kuan, W. L., Lin, R., Tyers, P., & Barker, R. A. (2007). The importance of A9 dopaminergic neurons in mediating the functional benefits of fetal ventralmesencephalon transplants and levodopainduced dyskinesias. Neurobiology of Disease, 25(3), 594-608.
13. Lee, C. S., Cenci, M. A., Schulzer, M., & Björklund, A. (2000). Embryonic ventral mesencephalic grafts improve levodopa-induced dyskinesia in a rat model of Parkinson's disease. Brain, 123, 1365-1379.
14. Levandis,G., Bazzini, E., Armentero, M.T.,Nappi,G.,&Blandini, F. (2008). Systemic administration of an mGluR5 antagonist, but not unilateral subthalamic lesion, counteracts l-DOPA-induced dyskinesias in a rodentmodel of Parkinson's disease. Neurobiology of Disease, 29(1), 161-168.
15. Meurers, B. H., Dziewczapolski, G., Shi, T., Bittner, A., Kamme, F., & Shults, C. W. (2009). Dopamine depletion induces distinct compensatory gene expression changes inDARPP-32 signal transduction cascades of striatonigral and striatopallidal neurons. Journal of Neuroscience, 29(21), 6828-6839.
16. Nishi, A., Bibb, J. A., Snyder, G. L., Higashi, H., Nairn, A. C., & Greengard, P. (2000). Amplification of dopaminergic signaling by a positive feedback loop. Proceedings of the National Academy of Sciences of the United States of America, 97(23), 12840-12845.
17. Nutt, J. G. (1990). Levodopa-induced dyskinesia: Review, observations, and speculations. Neurology, 40(2), 340-345.
18. Qin, Z. H., Chen, J., & Weiss, B. (1994). Lesions of mouse striatum induced by 6-hydroxydopamine differentially alter the density, rate of synthesis, and level of gene expression of D1 and D2 dopamine receptors. Journal of Neurochemistry, 62(2), 411-420.
19. Qu, D., Rashidian, J., Mount, M. P., Aleyasin, H., Parsanejad, M., Lira, A., et al. (2007). Role of Cdk5-mediated phosphorylation of Prx2 in MPTP toxicity and Parkinson's disease. Neuron, 55(1), 37-52
20. Ouimet, C. C., Miller, P. E., Hemmings, H. C. Jr., Walaas, S. I., & Greengard, P. (1984). DARPP-32, a dopamine- and adenosine 3′:5′- monophosphate-regulated phosphoprotein enriched in dopamine-innervated brain regions. III. Immunocytochemical localization. Journal of Neuroscience, 4(1), 111-124.
21. Papa, S. M., Engber, T. M., Kask, A. M., & Chase, T. N. (1994). Motor uctuations in levodopa treated parkinsonian rats: Relation to lesion extent and treatment duration. Brain Research, 662 (1-2), 69-74
22. Paxinos & Watson. (1998). The Rat Brain in Stereotaxic Coordinates.4. San Diego, CA: Academic Press.
23. Picconi, B., Centonze, D., Hakansson, K., Bernardi, G., Greengard, P., Fisone, G., et al. (2003). Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nature Neuroscience, 6, 501-506.
24. Scheggi, S., Rauggi, R., Nanni, G., Tagliamonte, A., & Gambarana, C. (2004). Repeated acetyl-l-carnitine administration increases phospho-Thr34 DARPP-32 levels and antagonizes cocaineinduced increase in Cdk5 and phospho-Thr75 DARPP-32 levels in rat striatum. European Journal of Neuroscience, 19(6), 1609-1620.
25. Smith, P. D., Crocker, S. J., Jackson-Lewis, V., Jordan-Sciutto, K. L., Hayley, S., Mount,M. P., et al. (2003). Cyclin-dependent kinase 5 is a mediator of dopaminergic neuron loss in a mouse model of Parkinson's disease. Proceedings of theNational Academy of Sciences of the United States of America, 100, 13650-13655.
26. Smith, P. D., Mount, M. P., Shree, R., Callaghan, S., Slack, R. S., Anisman, H., et al. (2006). Calpain-regulated p35/cdk5 plays a central role in dopaminergic neuron death through modulation of the transcription factor myocyte enhancer factor 2. Journal of Neuroscience, 26, 440-447.
27. Thomas, J., Wang, J., Takubo, H., Sheng, J., de, Jesus, S., & Bankiewicz, K. S. (1994). A 6-OHDA induced selective Parkinsonian rat model: Further biochemical and behavioural characterization. Experimental Neurology, 126(2), 159-167.